Studies have shown that a selection bias in bevacizumab eligibility in patients with NSCLC treated with chemotherapy,8 and that eligibility for bevacizumab use is independently associated with OS in patients with EGFR‐mutant NSCLC.14 This evidence concerns the gene EGFR and non-small cell lung carcinoma.